Methimazole
Methimazole has been studied in 1 paper since 2021: 1 observational study in people. The newest paper, Dec 30, 2021: “Immunometabolic signatures predict recovery from thyrotoxic myopathy in patients with Graves' disease”.
“In both patient groups, methimazole-induced euthyroidism was associated with improved handgrip strength and lower limb muscle function at 12 weeks.”
- 2 independent labs in 2 countries
- 1 trial, none about aging
- Funder: National Research Foundation of Korea
- Humans1
What did studies of Methimazole find?
3Studies of Methimazole measured 3 outcomes; the most studied are cellular senescence (2 studies), acylcarnitines (1) and handgrip strength (1).
Cellular senescence
downin human cells1downin humans1
2 studies
Cellular senescence
downin human cells1downin humans1
Methimazole decreases cellular senescence in human cells.
“Genetic knockdown or pharmacological inhibition of FMO1, as well as the clearance of senescent cells, reduced these hypertrophic and senescent phenotypes.”
CellsT3-induced chondrocyte hypertrophy
Free radical biology & medicine
Methimazole decreases cellular senescence in humans (P < 0.05).
“Senescent CD8+ CD28− CD57+ T-cell levels in peripheral blood were positively correlated with acylcarnitine levels (P < 0.05) and decreased during thyrotoxicosis recovery (P < 0.05).”
Human trialGraves' disease during thyrotoxicosis recoveryperipheral blood12 weeks
Journal of cachexia, sarcopenia and muscle
Acylcarnitines
downin humans1
1 study
Acylcarnitines
downin humans1
Methimazole decreases acylcarnitines in humans (P trend <0.01).
“Elevated plasma metabolites including acylcarnitines were restored to normal levels at Week 12 regardless of gender, body mass index, or age (P trend <0.01).”
Human trialGraves' disease during thyrotoxicosis recovery12 weeks
Journal of cachexia, sarcopenia and muscle
Handgrip strength
upin humans1
1 study
Handgrip strength
upin humans1
Methimazole improves handgrip strength in humans.
“In both patient groups, methimazole-induced euthyroidism was associated with improved handgrip strength and lower limb muscle function at 12 weeks.”
Human trialGraves' disease with thyrotoxic myopathyskeletal muscle12 weeks
Journal of cachexia, sarcopenia and muscle
Trial sponsors
Company1 trial30 people